Company:Beam Therapeutics
| Type | Public company |
|---|---|
| ISIN | US07373V1052 |
| Industry | Biotechnology |
| Founded | 2017 |
| Founders |
|
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people | |
Number of employees | 341 (December 31, 2021)[1] |
| Website | beamtx |
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods[vague].[2][3]
History
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]
In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6][7]
See also
References
- ↑ "Beam Therapeutics Inc. FORM 10-K". https://www.sec.gov/ix?doc=/Archives/edgar/data/1745999/000095017022002166/beam-20211231.htm.
- ↑ "Why Beam Therapeutics Climbed 64.5% in June". https://www.nasdaq.com/articles/why-beam-therapeutics-climbed-64.5-in-june-2021-07-08.
- ↑ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy" (in en-US). https://www.genengnews.com/news/base-editing-shows-promise-as-common-lung-and-liver-disease-therapy/.
- ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
- ↑ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma" (in en-US). https://www.businessinsider.com/biotech-gene-editing-crispr-intellia-beam-verve-inside-lab-2021-7.
- ↑ "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research.
- ↑ Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases" (in en-US). https://www.barrons.com/articles/pfizer-beam-therapeutics-gene-editing-diseases-partnership-51641678989.
External links
- Official website
- Business data for Beam Therapeutics Inc.:
 |  |
